Hosted on MSN28d
Tenecteplase No Longer Off-Label as Stroke Lytic
A clot-dissolving tissue plasminogen activator (tPA), tenecteplase is now indicated for acute ischemic stroke on top of its older approval in acute ST-elevation myocardial infarction. Tenecteplase ...
Pharmaceutical Technology28d
Genentech wins FDA approval for second stroke treatment
Genentech’s label expansion for TNKase consolidates its market position for pharmacological stroke treatments.
Endovascular Today4d
SonoVascular SonoThrombectomy System FIH Study Presented With Initial Results
SonoVascular, Inc. recently announced it has successfully completed an initial set of eight cases in patients with deep vein thro ...
PMLiVE27d
Roche’s Genentech granted FDA approval for TNKase in acute ischaemic stroke
TNKase is a tissue plasminogen activator, clot-dissolving, thrombolytic medicine that starts a biochemical reaction that can break down fibrin, a component of blood clots. Until now, the only ...